Member access

4-Traders Homepage  >  Shares  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)

326
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
04/15/2015 04/16/2015 04/17/2015 04/20/2015 04/21/2015 Date
71.45(c) 70.96(c) 68.97(c) 69.71(c) 69.42 Last
280 929 225 025 377 897 180 434 60 244 Volume
-0.11% -0.69% -2.80% +1.07% -0.42% Change
More quotes
Financials (€)
Sales 2015 3 617 M
EBIT 2015 528 M
Net income 2015 294 M
Debt 2015 1 422 M
Yield 2015 1,68%
Sales 2016 3 916 M
EBIT 2016 676 M
Net income 2016 408 M
Debt 2016 1 254 M
Yield 2016 1,82%
PER 2015 42,14
PER 2016 28,46
EV / Sales 2015 4,14x
EV / Sales 2016 3,78x
Capitalization 13 559 M
More Financials
Company
UCB SA is a biopharmaceutical company that engages in the research, development and commercialization of innovative drugs in the fields of central nervous system and immunology disorders.It focuses on the discovery and development of innovative medicines and solutions to transform the lives of... 
Sector
Pharmaceuticals
Calendar
04/30Earnings Release
More about the company
Surperformance© ratings of UCB
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB
04/02 DR REDDY LABORATORIES : Labs to Acquire Brands Portfolio of UCB for USD128 Milli..
03/30 Ireland's Horizon to buy U.S. drugmaker Hyperion for $1.1 billion
03/27 UCB : Convening notice to attend the general meeting of shareholders
03/25 UCB : Findings from UCB Pharma SA Yields New Findings on Toxicology (Identificat..
02/12 UCB : Patent Issued for Systems for Administering Medication
02/12 UCB : Patent Issued for Syringe Safety Assembly
01/28 UCB : announces US and EU regulatory filings for the investigational antiepilept..
01/12 UCB : Update of transparency notification UCB SA/NV
More news
Sector news : Biopharmaceuticals
03:16aDJPublicis Posts Sales Jump
03:14a GLAXOSMITHKLINE : *bernstein raises glaxosmithkline-price target to 1541 pence -..
03:13a ASTRAZENECA : *bernstein raises astrazeneca price target to 5098 pence - 'market..
More sector news : Biopharmaceuticals
News from SeekingAlpha
02/08 WEEK IN REVIEW : WuXi NextCode Leads $15 Million Financing In Claritas Genomics


Comments 
Advertisement
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF